Skip to main content
OpenTrials
Completed

NCT Number: NCT02137577

AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China

The purpose of this study is to determine whether DEB is more effective than common PTA balloon using under in long-term vessel patency and inhibiting restenosis in the infrapopliteal artery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking Union Medical College Hospital, Beijing, China

Loading trial locations.

About this study

PTA is an established alternative to open surgical bypass for the treatment of infrainginual disease of critical limb ischemia.

DEBs are designed to promote arterial patency by reducing neointimal proliferation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 85 years
  • Patients with peripheral artery disease (PAD), with Rutherford classification between 4 and 6
  • an occlusion or a minimum grade of stenosis Primary over 70% in the below popliteal artery
  • The expected survival time is more than 1 year
  • signed Patient informed consent form

Exclusion criteria

  • Serum creatinine clearance rate less than 30ml/min in patients
  • patients with acute thrombosis requiring lysis or thrombectomy
  • patient with a lysis or an lower limb intervention as a therapy within the last 6 weeks
  • patient requiring intervention in both lower limbs at the same time
  • In-stent restenosis in the blow-knee popliteal artery
  • target lesion can't be cross by the guide wire
  • the stenosis rate of proximal outflow more than 30% with or without intervention
  • the length of the stenosis or occlusion in proximal outflow(including the Iliac artery, the superficial femoral artery, the Popliteal artery) more than 150mm before intervention
  • stenosis or occlusion of distal outflow for below-the-ankle artery.
  • expected major amputations at the index limb before intervention
  • known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc.
  • patients participating in another clinical trials with interfere with this trial in the same time
  • pregnancy and lactating woman
  • untreatable bleeding diatheses

Treatment and study plan

DEB catheter

Procedure

DEB catheter (trade name: Litos/Tulip)

common PTA balloon catheter

Procedure

common PTA balloon catheter

Primary outcomes

  1. Primary Patency [Time Frame: 6 months]

    Time frame: 6 months

    Freedom from target vessel occlusion and clinically driven target lesion reintervention

Secondary outcomes

  1. device success rate

    Time frame: during the operation(after using the DEB catheter)

    DEB catheter can reach the target lesions, expand as expected(not broken), and withdraw successfully.

  2. technical success rates

    Time frame: during the operation(after using the DEB catheter)

    The blood supply of the target lesion recovered after treatment, and residual stenosis less than 50%

  3. operation success rate

    Time frame: during the operation(after using the DEB catheter)

    both device succeed and technical succeed, and without clinical complication

  4. if occured clinically driven TLR( target lesion revascularization)

    Time frame: 6 months, 12 months,18 months, 24 months

    Clinically driven TLR is defined as revascularization performed on a patient who returns with clinical symptoms such as: resting pain occur again, ulcer deterioration, new foot ulcers

  5. target lesion late lumen loss 6 months

    Time frame: 6 months

    measure difference of the MLD(minimal lumen diameter) at 0 time and 6 months

  6. Ulcer healing rate

    Time frame: 6 months, 12 months

    Healed or not, if not, improving,stagnant, worsening

  7. Ulcer healing time

    Time frame: 6 months, 12 months, 18 months, 24 months

    Healed or not

  8. Change from baseline ankle brachial index(ABI) at 6 months

    Time frame: 6 months

    measure ankle brachial index

    >1.3 Vascular wall calcification is severe

    0.9~1.1 Normal range

    0.5~0.8 Mild and moderate ischemia of lower limb arteries

    <0.5 severe ischemia

  9. change from baseline Rutherford stage at 6 months

    Time frame: 6 months, 12 months,18 months, 24 months

    based the following definition of Rutherford stage, evaluate the stage of patient. Then compare the stage of patient just after procedure and 6 months after treatment

    Stage clinical symptom

    0 asymptomatic

    • mild claudication
    • moderate claudication
    • severe claudication
    • ischemic rest pain
    • minor tissue loss
    • ulceration or gangrene
  10. limb salvage in surviving subjects

    Time frame: 30 days, 6 months, 12 months,18 months, 24 months

    No Amputation of target limb

Sponsors and collaborators

Lead sponsor

Acotec Scientific Co., Ltd

Industry

Registry information

Official study title

Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure of the Infrapopliteal Artery

Important dates

Study start
2014
Primary completion
2018
Study completion
2020
First posted
May 14, 2014
Registry last updated
Jun 18, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.